The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 16, 2026 for Renosen Pharmaceuticals Pvt Ltd
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals informed the exchanges about a pledge release by Renosen Pharmaceuticals Private Limited, a Promoter Group entity. The pledge on 4,00,000 equity shares (about 0.87% of total share capital) was released on February 13, 2026, with the disclosure filed on February 16, 2026. After this release, Renosen Pharmaceuticals holds 27,08,719 shares (5.88% of total capital) with zero encumbered shares remaining. The disclosure was made under SEBI's SAST Regulations, 2011. Other promoter and promoter group entities listed in the table show no changes to their pledged holdings in this filing.
This is a positive signal for shareholders — the promoter group has reduced its pledged holdings to zero, lowering the risk of any forced selling or margin-call driven share dump. It also suggests improved liquidity or loan repayment by the promoter group entity.